Advertisement

Ads Placeholder
Loading...

Exelixis, Inc.

EXELNASDAQ
Healthcare
Biotechnology
$43.88
$-0.16(-0.36%)
U.S. Market opens in 32h 11m

Exelixis, Inc. (EXEL) Stock Overview

Explore Exelixis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap11.8B
P/E Ratio15.23
EPS (TTM)$2.78
ROE0.37%
Fundamental Analysis

AI Price Forecasts

1 Month$36.77
3 Months$44.24
1 Year Target$56.67

EXEL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Exelixis, Inc. (EXEL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 60.11, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $56.67.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 15.23 and a market capitalization of 11.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.36%
5-Day Change
3.59%
1-Month Change
7.71%
3-Month Change
0.69%
6-Month Change
9.45%
Year-to-Date (YTD) Change
0.69%
1-Year Change
19.63%
3-Year Change
125.26%
5-Year Change
86.88%
All-Time (Max) Change
197.49%

Contact Information

650 837 7000
1851 Harbor Bay Parkway, Alameda, CA, 94502

Company Facts

11,470 Employees
IPO DateApr 17, 2000
CountryUS
Actively Trading

Frequently Asked Questions